Rodeo Therapeutics is a preclinical-stage biopharmaceutical company. It is focused on novel enzyme target and biological pathway that play a critical role in tissue repair and regeneration. Rodeo’s initial goal is to develop novel small molecules therapies for the treatment of inflammatory bowel disease and the promotion of blood cell reconstitution following bone marrow transplant.
Rodeo Therapeutics total Funding
Rodeo Therapeutics latest funding size
Time since last funding
|a year ago|
Rodeo Therapeutics investors
|WuXi AppTecwdxefcqufszuzezftuxetqsqxt, Accelerator Corporation, Johnson & Johnson Innovation, AbbVie Biotech Ventures, Watson Fund, ARCH Venture Partners, WRF Capital, Eli Lilly, Alexandria Venture Investments|
Who are Rodeo Therapeutics key executives?
Rodeo Therapeutics's key executives are Sanford Markowitz, Joseph Ready and Stanton Gerson.
Who are Rodeo Therapeutics competitors?
Competitors of Rodeo Therapeutics include Sigilon, Creative Peptides and Ncardia.
Where is Rodeo Therapeutics headquarters?
Rodeo Therapeutics headquarters is located at 200 1616 Eastlake Ave E, Seattle.
Where are Rodeo Therapeutics offices?
Rodeo Therapeutics has an office in Seattle.
How many offices does Rodeo Therapeutics have?
Rodeo Therapeutics has 1 office.